4-4-甲氧基苯氧基哌啶 | 162402-33-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-4-甲氧基苯氧基哌啶
• 中文别名: 4-(4-甲氧基苯氧基)哌啶
• 英文名称: 4-(4-methoxyphenoxy)piperidine
• CAS: 162402-33-7
• 化学式: C₁₂H₁₇NO₂
• mdl: MFCD08059670
• 分子量: 207.272
• InChiKey: HRMYEAQYLDCUGG-UHFFFAOYSA-N

物化性质

• 沸点：
  326.2±32.0 °C(Predicted)
• 密度：
  1.057±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H319
• 危险性防范说明：
  P305 + P351 + P338

反应信息

• 作为反应物：
  描述：

  4-4-甲氧基苯氧基哌啶 在 palladium diacetate 、 4-甲基苯磺酸吡啶 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 乙醇 、 caesium carbonate 作用下， 以 甲苯 为溶剂， 反应 24.5h， 生成 4-[4-(4-甲氧基苯氧基)哌啶-1-基]苯酚
  参考文献：
  名称：

  Synthesis and Antituberculosis Activity of a Novel Series of Optically Active 6-Nitro-2,3-dihydroimidazo[2,1-b]oxazoles

  摘要：

  In an effort to develop potent new antituberculosis agents that would be effective against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis, we prepared a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles substituted at the 2-position with various phenoxymethyl groups and a methyl group and investigated the in vitro and in vivo activity of these compounds. Several of these derivatives showed potent in vitro and in vivo activity, and compound 19 (OPC-67683) in particular displayed excellent in vitro activity against both drug-susceptible and drug-resistant strains of M. tuberculosis H(37)Rv (MIC = 0.006 mu g/mL) and dose-dependent and significant in vivo efficacy at lower oral doses than rifampicin in mouse models infected with M. tuberculosis Kurono. The synthesis and structure-activity relationships of these new compounds are presented.

  DOI：

  10.1021/jm060957y
• 作为产物：
  描述：

  3-p-methoxyphenyl-5(S)-[(4-p-methoxyphenoxypiperidino)methyl]-2-oxazolidinone 以 二甲基亚砜 为溶剂， 生成 4-4-甲氧基苯氧基哌啶
  参考文献：
  名称：

  4-aryloxy- and 4-arylthiopiperidine derivatives

  摘要：

  公式I中的新颖的4-芳氧基或4-芳硫基哌啶衍生物，其中R.sup.1和R.sup.2各自独立地是苯基基团，其未被取代或被A、OH、OA、具有6-10个C原子的芳基氧基、具有7-11个C原子的芳基烷氧基、--0--(CH.sub.2).sub.n --0--、Hal、CF.sub.3、NO.sub.2、NH.sub.2、NHA、NA.sub.2、NHAc、NAAc、NHSO.sub.2A和/或NASO.sub.2A单取代或双取代，其中X是O、S、SO或SO.sub.2，m为1、2或3，n为1或2，A是具有1-6个C原子的烷基基团，Hal是F、Cl、Br或l，Ac是具有1-8个C原子的脂肪酰基、具有1-10个C原子的芳基烷酰基或具有7-11个C原子的芳酰基，以及其生理上可接受的盐，表现出对中枢神经系统有影响，特别是对神经精神病的影响，具有可忽略的僵直效应。

  公开号：

  US05561145A1

文献信息

• [EN] HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR<br/>[FR] MODULATEURS ALLOSTÉRIQUES D'ÉTHER DE PIPÉRIDINE D'HÉTÉROARYLE DU RÉCEPTEUR DE L'ACÉTYLCHOLINE MUSCARINIQUE M4
  申请人：MERCK SHARP & DOHME

  公开号：WO2018118734A1

  公开（公告）日：2018-06-28

  The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及异芳基哌啶醚化合物，其为M4肌氨酸乙酰胆碱受体的变构调节剂。本发明还涉及所述化合物在潜在的治疗或预防M4肌氨酸乙酰胆碱受体参与的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗M4肌氨酸乙酰胆碱受体参与的疾病中的用途。
• [EN] NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS COMME BLOQUEURS DES CANAUX CALCIQUES
  申请人：ABBOTT LAB

  公开号：WO2010039947A1

  公开（公告）日：2010-04-08

  The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar1, Ar2, L1, L2, n, R1, R4, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有式（I）化合物的钙通道抑制剂，其中Ar1、Ar2、L1、L2、n、R1、R4、X和Y如规范中所定义。本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病和疾病的方法。
• Substituted phenyl methanone derivatives
  申请人：Jolidon Synese

  公开号：US20060160788A1

  公开（公告）日：2006-07-20

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 3 , n, and m, are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors of the glycine transporter 1 (GlyT-1) and are useful for the treatment of CNS disorders such as schizophrenia, cognitive impairment, and Alzheimer's disease.

  本发明涉及以下式I的化合物：其中R1、R2、R3、n和m如规范中所定义，并且其药用可接受的酸盐。这些化合物是甘氨酸转运蛋白1（GlyT-1）的良好抑制剂，可用于治疗中枢神经系统疾病，如精神分裂症、认知障碍和阿尔茨海默病。
• [EN] SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION<br/>[FR] AMINOQUINOLONES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE DGKALPHA POUR ACTIVATION IMMUNITAIRE
  申请人：BAYER AG

  公开号：WO2021105115A1

  公开（公告）日：2021-06-03

  The present invention covers aminoquinolone compounds of general formula (I) : in which R1, R2, R3, R4, R5, R6, R7, R8, X and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式(I)的氨基喹啉化合物：其中R1、R2、R3、R4、R5、R6、R7、R8、X和n如此处所定义，制备所述化合物的方法，制备所述化合物有用的中间体化合物，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗和/或预防疾病的药物组合物，特别是对二酰基甘油激酶α调节性疾病的治疗，作为单一药剂或与其他活性成分组合使用。
• PREPARATION OF (N-HETEROCYCLYL) ARYL ETHERS
  申请人：Kreis Michael

  公开号：US20100152454A1

  公开（公告）日：2010-06-17

  The present invention relates to a process for the preparation of optionally substituted (N-heterocyclyl) aryl ethers.

  本发明涉及一种制备可选取代的（N-杂环基）芳基醚的方法。